Bank of America’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-99,105
| Closed | -$2.39M | – | 8173 |
|
|
2023
Q1 | $2.39M | Buy |
99,105
+49,399
| +99% | +$620K | ﹤0.01% | 4198 |
|
|
2022
Q4 | $525K | Sell |
49,706
-17,471
| -26% | -$141K | ﹤0.01% | 5343 |
|
|
2022
Q3 | $303K | Sell |
67,177
-7,484
| -10% | -$34.1K | ﹤0.01% | 5736 |
|
|
2022
Q2 | $298K | Buy |
74,661
+21,761
| +41% | +$103K | ﹤0.01% | 5805 |
|
|
2022
Q1 | $388K | Sell |
52,900
-49,926
| -49% | -$299K | ﹤0.01% | 6007 |
|
|
2021
Q4 | $578K | Buy |
102,826
+62,725
| +156% | +$398K | ﹤0.01% | 5744 |
|
|
2021
Q3 | $256K | Buy |
40,101
+2,898
| +8% | +$18.6K | ﹤0.01% | 6135 |
|
|
2021
Q2 | $313K | Sell |
37,203
-8,518
| -19% | -$68.7K | ﹤0.01% | 5773 |
|
|
2021
Q1 | $479K | Buy |
45,721
+18,418
| +67% | +$259K | ﹤0.01% | 5407 |
|
|
2020
Q4 | $462K | Sell |
27,303
-17,185
| -39% | -$258K | ﹤0.01% | 5066 |
|
|
2020
Q3 | $571K | Sell |
44,488
-17,735
| -29% | -$224K | ﹤0.01% | 4613 |
|
|
2020
Q2 | $877K | Buy |
62,223
+35,521
| +133% | +$448K | ﹤0.01% | 4213 |
|
|
2020
Q1 | $246K | Buy |
26,702
+19,702
| +281% | +$254K | ﹤0.01% | 4967 |
|
|
2019
Q4 | $105K | Buy |
7,000
+1,532
| +28% | +$13.7K | ﹤0.01% | 5980 |
|
|
2019
Q3 | $37K | Buy |
5,468
+5,043
| +1,187% | +$51K | ﹤0.01% | 6423 |
|
|
2019
Q2 | $5K | Buy |
+425
| New | +$2.31K | ﹤0.01% | 6855 |
|
|
2019
Q1 | – | Sell |
-739
| Closed | -$1K | – | 7511 |
|
|
2018
Q4 | $1K | Buy |
+739
| New | +$2.12K | ﹤0.01% | 7017 |
|
Other funds holding PRVB
Bank of America's PRVB Position: Q2 2023 in Review
Bank of America sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 99,105 shares — an estimated $2.39M sold.
Bank of America first reported a position in PRVB in Q4 2018 and held it in 17 quarters. The position peaked at $2.39M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Bank of America reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Bank of America sold 99,105 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $2.39M.
- Bank of America first reported a position in Provention Bio, Inc. Common Stock in Q4 2018 and held it in 17 quarters.
- Bank of America's Provention Bio, Inc. Common Stock position peaked at $2.39M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Bank of America's 13F filing for Q2 2023, filed 14 Aug 2023.